WASHINGTON, D.C. — March 24, 2016 — The Sabin Vaccine Institute (Sabin) today announced the appointment of Amy Finan as its next chief executive officer, following a global search by its Board of Trustees. Finan, currently the senior vice president responsible for business development with the Biotechnology Innovation Organization (BIO), the world's largest membership organization representing biotechnology companies, academic institutions, and state biotechnology centers, will assume her new role with Sabin on April 18, 2016.
“Amy is an exceptional leader who blends decades of experience in life sciences with the business acumen, advocacy skills, and effective business development and relationship-building abilities required to lead this dynamic and multidimensional non-profit organization,” said Dr. Axel Hoos, Chair of the Board of Trustees at Sabin. “Sabin is at the forefront of many of the world’s most pressing health issues and Amy’s record of growth, innovation and partnership development will help to propel the organization into new, exciting territory.”
During her 11-year tenure with BIO, Finan played a critical role in expanding the organization’s membership and revenue base and implementing forward-leaning approaches to fundraising, branding, marketing and programming. In 2011 and simultaneous with her BIO responsibilities, she also served as president of the Biotechnology Institute, an organization founded by BIO in 1998 to promote life science education. Prior to BIO, Finan led corporate communications and investor relations for the former clinical-stage biotechnology company EntreMed Inc., and directed regional government relations for the National Association of Biomedical Research.
“I am honored to join Sabin at such a pivotal moment in the organization’s history,” said Finan. “Sabin’s proven capabilities in advocacy, communications and early stage vaccine research and development are strongly suited to today’s dynamic global health landscape. With an array of health challenges facing the world’s most vulnerable communities, we have an imperative to act and I look forward to working with the talented team at Sabin, as well as our global network of partners, to champion proven policy and technical solutions.”
Finan succeeds Ambassador Michael W. Marine, who will retire on April 15, 2016. Under Ambassador Marine’s leadership for six years, Sabin expanded its advocacy programs for vaccine-preventable diseases and neglected tropical diseases (NTDs), grew its vaccine development program through a partnership with Texas Children’s Hospital and Baylor College of Medicine, and launched END7, the world’s largest grassroots advocacy campaign supporting NTD control and elimination programs.
About the Sabin Vaccine Institute
The Sabin Vaccine Institute (Sabin) is a non-profit, 501(c)(3) organization of scientists, researchers and advocates dedicated to reducing needless human suffering from vaccine-preventable and neglected tropical diseases (NTDs). Since its founding in 1993 in honor of Dr. Albert B. Sabin, the developer of the oral polio vaccine, Sabin has been at the forefront of global efforts to eliminate, prevent and cure infectious and neglected tropical diseases. Sabin develops new vaccines, advocates for increased use of existing vaccines and promotes expanded access to affordable medical treatments in collaboration with governments, academic institutions, scientists, medical professionals and other non-profit organizations. For more information, please visit www.sabin.org
+1 (202) 621-1691